

<b>Reference number</b>
2438-H

## SPECIALTY QUANTITY LIMIT PROGRAM

### Tagrisso (osimertinib)

#### I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization

#### II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Tagrisso 40 mg tablets	30 per 30 days	None	Standard dosing: 80 mg per day  Severe toxicities, QTc interval prolongation: 40 mg per day
Tagrisso 80 mg tablets	30 per 30 days	60 per 30 days	Drug interaction, coadministration with a strong CYP3A4 inducer: 160 mg (two 80 mg tablets) per day

\*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

#### III. REFERENCES

1. Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; August 2018.